Purchase this article with an account.
J.A. Gow, B.A. Aird, T.R. McNamara, C.K. Song, T.W. Joe, G.A. Baklayan; The Compatibility of Vitrase® Combined with Kenalog® . Invest. Ophthalmol. Vis. Sci. 2006;47(13):688.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the compatibility of Vitrase® (hyaluronidase for injection) lyophilized, ovine (6200 USP units/vial) and Kenalog®–40 (triamcinolone acetonide, 40 mg/mL), when combined.
Vitrase (6200 USP units/vial) was reconstituted with 0.54 mL of sterile, unpreserved normal saline (0.9% sodium chloride for injection) and combined with Kenalog to obtain a concentration of approximately 68 USP units per 100 µL of Kenalog. This Vitrase/ Kenalog mixture used is a 1:1 clinical dose ratio. Hyaluronidase activity in the presence and absence of Kenalog was determined using a viscometric method derived from the European Pharmacopeia procedure.
Vitrase activity remained unchanged for the sample preparation (68 USP units per 100 µL of Kenalog) after 24 hours.
Hyaluronidase activity remained unchanged for a sample concentration of Vitrase prepared at 68 USP units per 100 µL of Kenalog after 24 hours. In the in vitro setting, Vitrase was found to retain full biological activity and stability when combined with Kenalog.
This PDF is available to Subscribers Only